Safety and Efficacy of RO4929097 in Combination With Temsirolimus: A Pharmacokinetic and Pharmacodynamic Phase I Study in Patients With Advanced Solid Tumours With an Expansion of Cohort With Patients With Recurrent/Metastatic Endometrial and Renal Cell Cancers
This phase I trial is studying the side effects and best dose of giving
gamma-secretase/Notch signalling pathway inhibitor RO4929097 and temsirolimus together in
treating patients with advanced solid tumours. Gamma-secretase/Notch signalling pathway
inhibitor RO4929097 and temsirolimus may stop the growth of tumour cells by blocking some of
the enzymes needed for cell growth.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society